# This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.

> **NCT06074497** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Kangabio AUSTRALIA LTD PTY** · enrollment: 54 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** KGX101- Cohort -1
- **DRUG:** KGX101- Cohort 1
- **DRUG:** KGX101- Cohort 2
- **DRUG:** KGX101- Cohort 3
- **DRUG:** KGX101- Cohort 4
- **DRUG:** KGX101- Cohort 5
- **DRUG:** KGX101 and Envafolimab

## Key facts

- **NCT ID:** NCT06074497
- **Lead sponsor:** Kangabio AUSTRALIA LTD PTY
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-13
- **Primary completion:** 2026-05-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06074497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06074497, "This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06074497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*